9-ING-41 (Synonyms: Elraglusib) |
Catalog No.GC39152 |
9-ING-41 es un inhibidor de la glucÓgeno sintasa quinasa-3β (GSK-3β) selectivo y competitivo con ATP basado en maleimida con una IC50 de 0,71 μM. 9-ING-41 conduce significativamente a la detenciÓn del ciclo celular, la autofagia y la apoptosis en las células cancerosas. 9-ING-41 tiene actividad anticancerÍgena y tiene el potencial de potenciar los efectos antitumorales de los fÁrmacos quimioterapéuticos.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1034895-42-5
Sample solution is provided at 25 µL, 10mM.
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
[1]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. [2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.
Average Rating: 5
(Based on Reviews and 27 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *